New England Healthcare Executive Network - Surgical and Medical Innovations in Lung and Respiratory Health

Description

The Lung Center at Brigham and Women's Hospital provides comprehensive care for lung patients. Our keynote speaker is Dr. Raphael Bueno, Division Chief of Thoracic Surgery at the Brigham. Dr. Bueno's primary research involves the development of novel translational tools in genomics that can be used to identify candidate predictive and diagnostic markers for cancer, as well as novel targets for therapy, specifically mesothelioma and lung cancer. He will share his experiences and development of Image-guided Video Assisted Thoracoscopic Surgery (iVATS) technology for minimally invasive identification and removal of early stage lung tumors and other soft tissue cancers. Come join this timely, keynote presentation and blue-ribbon panel of experts as they discuss patient management and innovations in thoracic surgery. Ask them questions and contribute your insights during the audience interactive segment. Identify potential new businesses opportunities in lung and respiratory health. Keynote Speaker: Raphael Bueno, M.D., Chief, Division of Thoracic Surgery, Co-Director, Brigham and Women's Lung Center, Vice Chairman of Surgery for Cancer and Translational Research, Fredric G. Levin Distinguished Chair in Thoracic Surgery and Lung Cancer Research, Professor, Harvard Medical School As Chief of thoracic surgery and professor of surgery at Harvard Medical School, Dr. Bueno is a National Cancer Institute-funded investigator who combines translational research with a general thoracic surgery practice. Panel Moderated by: Jules Fried, CEO, Vasogenesis LLC Jules is a serial entrepreneur, co-founder, and Chief Executive officer of Vasogenesis LLC, a clinical stage drug company repurposing an off-patent biologic to treat vascular disease. Panelists: Michael D'Amore, PhamD, MBA, Sr. Medical Science Liaison, Genentech At Genentech Michael cultivates relationships with the scientific and medical community serving as a scientific resource, supporting new drugs and upcoming advances in cancer treatments, and providing input about relevant scientific and clinical data to ensure strong understanding of evolving patient treatment trends. Scott Frushour, Sr. Principle Engineer, Lung Health, Medtronic For Medtronic Scott’s, focuses on thoracic disease innovation and the assessment of novel technologies and solutions that aim to improve patient care across the thoracic disease spectrum. Alan D. Lucas, CEO and Cofounder, Navigation Sciences, Inc. Navigation is developing novel, Image-guided technology for minimally invasive identification and removal of early stage lung lesions and other soft tissue tumors. The technology, which combines intraoperative imaging with Augmented Reality (AR), promises to improve surgical outcomes and increase operational efficiency. Randolph Setser, PhD. Senior Staff Scientist, Siemens Healthineers Advanced Therapies Randy manages research collaborations focused on multi-specialty interventional applications as the team lead for interventional cardiovascular MR and interventional pulmonology applications for Siemens Healthineers. Pierre R. Theodore, M.D., Vice President Global External Innovation, Johnson and Johnson As the Vice President of Global External Innovation at Johnson & Johnson Dr. Theodore is responsible to help accelerate novel technologies to advance the standard of care in the management of patients with cancer. Join this timely program to hear about future focused, clinical insights in the management of thoracic disease. Who should attend: C-level executives, board members, healthcare providers, venture capital and private equity investors, and anyone who wants a better understanding of opportunities and pitfalls of the collaboration between healthcare professionals, tech companies and patients. Speaker Biographies: Raphael Bueno, M.D., Chief, Division of Thoracic Surgery, Co-Director, Brigham and Women's Lung Center, Vice Chairman of Surgery for Cancer and Translational Research, Fredric G. Levin Distinguished Chair in Thoracic Surgery and Lung Cancer Research, Professor, Harvard Medical School Dr. Raphael Bueno is the Chief of Thoracic Surgery at Brigham and Women’s Hospital. He completed his medical training at Harvard Medical School and MIT’s Health Sciences and Technology program. He subsequently trained in General Surgery at Brigham and Women’s Hospital and Thoracic and Cardiac Surgery at Massachusetts General Hospital. He joined the BWH Thoracic Faculty in 1996. He was promoted to the rank of Professor of Surgery in 2011 and was appointed Chief of the Division of thoracic surgery in 2014. In 2017 Dr. Bueno was promoted to the Frederic G Levin Distinguished Chair of Thoracic Surgery and Lung Cancer Research at BWH. Dr. Bueno’s main research interests center on the molecular events that lead to malignancy in mesothelioma and lung cancer. Specifically, Dr. Bueno focuses on developing and fine-tuning biomarkers for diagnosis, prognostis and prediction in these cancers. His research also includes tumor sequencing of Mesothelioma and identification of targetable pathways. Dr. Bueno’s research has been funded by the NCI for over 15 years, DOD, and several pharmacological and device companies. His lab’s molecular research is closely integrated with the tumor bank. Clinically and administratively, Dr. Bueno supervises a division of 18 thoracic surgeons who work at the BWH and 5 additional network hospital performing nearly 5,000 general thoracic surgical cases of all types per year. In addition, he is the surgical director of the BWH Lung Center and a co-director of the Lung Research Center. His personal surgical practice is focused on cancer surgery including mesothelioma, lung and esophageal cancer. He performs approximately 350 operations per year and actively participates in resident education and mentorship. Michael D'Amore, PhamD, MBA, Sr. Medical Science Liaison, Genentech Michael is a Lung / GU Medical Science Liaisons (MSL) at Genentech for the New England area responsible for building and cultivating relationships with the scientific and medical community regarding upcoming advances in cancer treatments, and providing input about relevant scientific and clinical data to ensure strong understanding of evolving patient treatment. Michael joined Genentech in 2010 from Wyeth where he worked as a Clinical Scientist, writing clinical protocols and as a MSL. Prior to Wyeth, Michael was at St. Elizabeth’s Medical Center as a research/clinical pharmacist. Jules Fried, CEO, Vasogenesis LLC Jules Fried is a serial entrepreneur, co-founder, and Chief Executive officer of Vasogenesis LLC, a clinical stage drug company repurposing an off patent biologic to treat vascular disease without surgical intervention. Before Vasogenesis, Jules was CEO of Interactive Motion Technologies, a manufacturer of robotic rehabilitation equipment for stroke victims which he sold to a microcap public company. He was also a Principal at Atlantic VIC, a technology venture development company licensing technology out of local research institutions, and founder and board member of First Commons Bank, one of the fastest growing community banks in the country, sold last year to Brookline Bank. Earlier in his career, he built and led a two-time Inc. 500 digital printing peripheral equipment manufacturer as a member of the founding management team. Before that, Jules was a partner in the law firm of McDermott, Will & Emery, having co-founded a boutique health care law firm that became their Boston office. Mr. Fried started his legal career in the Antitrust Division of the US Department of Justice and was part of the team responsible for the litigation resulting in the breakup of AT&T. He has a J.D cum laude from the University of Michigan Law School, and is an A.B. from Princeton University. Jules has led many successful NEHEN programs. Scott Frushour, Sr. Principle Engineer, Lung Health, Medtronic Scott brings over 20 years of experience in technology, 12 with Medtronic, formerly Covidien, the last 6 focusing on thoracic disease innovation. Scott has become a sought-after resource in the assessment of novel technologies and solutions that aim to improve patient care across the thoracic disease spectrum. He is recognized as a subject matter expert in the rapidly evolving technology landscape within the Lung Cancer continuum of care and the impact it has on patient survival. In his role, Scott leads business and technology assessments that contribute to a growing portfolio of products that help to capture patients, improve diagnostics, optimize therapy and accelerate recovery for patients suspected or confirmed to have lung cancer. Assessments led by Scott have contributed over $400M+ to the Medtronic Portfolio. Scott’s formal training is in Electrical Engineering and he is a named inventor on over 80 patents globally. Alan D. Lucas, CEO, Navigation Sciences, Inc. Alan Lucas has served in business development and marketing positions along with consulting for development stage and emerging medical technology companies for more than 25 years. He has global senior management experience enhancing investor value, including execution of successful cross boarder M&A transactions, fundraising, IPO’s and private placements. He has diverse product and cross functional expertise in medical technology, with emphasis in procedure-specific devices and implants used in orthopedics, cardiovascular, general surgery, radiation oncology, minimally invasive surgery; and knowledge of intellectual property portfolio development. Alan has negotiated supply agreements, distributor relationships and licensing agreements. He has also directed market analysis including; regulatory, payer, product specification, product launch, and sales management. In 2009, Alan founded the New England Healthcare Executive Network (NEHEN). NEHEN is a professional organization that encourages collaboration within the New England healthcare ecosystem through monthly educational networking events. Membership includes over 2,000 senior executives, healthcare providers, academia, investors, and represents a broad range of market verticals including biotechnology, pharmaceuticals, medical devices, and health IT. Randolph Setser, PhD. Senior Staff Scientist, Siemens Healthineers Advanced Therapies Randolph is a biomedical engineer with 19 years experience in research and teaching in academic medical centers and industry, with expertise in medical imaging and image-guided therapies. In his current role, he manages research collaborations focused on multi-specialty interventional applications at medical centers primarily in the Southeastern U.S. Within this research collaborations group, he serves as team lead for interventional cardiovascular MR and interventional pulmonology applications. Prior to Siemens, Randolph was cardiovascular imaging scientist for the Department of Radiology at Cleveland Clinic, focusing on cardiovascular MRI. Pierre R. Theodore, M.D., Vice President Global External Innovation, Johnson and Johnson Pierre R. Theodore is a Thoracic Surgeon focusing on disease of the lung, esophagus and chest wall and thoracic organ transplantation. In addition to his clinical activities, Dr. Theodore is a Vice President of Global External Innovation at Johnson & Johnson In this role, he is responsible to help accelerate novel technologies to advance the standard of care in the management of patients with cancer. Dr. Theodore comes to the faculty at Stanford after many years on faculty at the University of California at San Francisco. He has over two decades of experience in cardiothoracic surgery, surgical education, entrepreneurship and innovation. Pierre’s practice has focused on minimally invasive surgical approaches in thoracic surgery, interventional pulmonary procedures, and Global Surgery initiatives to expand surgical capacity in low-income countries. Pierre has served as an advisor to numerous venture capital and private equity firms in Silicon Valley, helping to guide strategy in healthcare investments across the digital health, biotech, and medical device sectors. Pierre is a commissioned officer in the United States Navy Reserve Medical Officer Corps, holding the rank of Commander. After obtaining an undergraduate degree in Philosophy from Princeton University, Pierre received his Doctor of Medicine from the University of Virginia. He completed general surgical and cardiothoracic surgical training at Johns Hopkins Hospital and Hôpital Universitaire Pitié-Salpêtrière in Paris. Pierre completed a post-doctoral fellowship at the Massachusetts General Hospital Transplant Biology Research Center, Harvard Medical School.